Open Access Full Text Article

Long Noncoding RNA ST7-AS1 Upregulates TRPM7 Expression by Sponging microRNA-543 to Promote Cervical Cancer Progression [Retraction]

Qi H, Lu L, Wang L. Onco Targets Ther. 2020;13:7257-7269.

We, the Editor and Publisher of *OncoTargets and Therapy* are retracting the published article. Since publication, concerns have been raised about the duplication of images in this article with those from other unrelated articles. Specifically,

- The image from Figure 4E, SiHa, si-NC, has been duplicated with the image from Figure 4E, T98, siNC, from Yang H, Song Z, Wu X, Wu Y, Liu C. MicroRNA-652 suppresses malignant phenotypes in glioblastoma multiforme via FOXK1-mediated AKT/mTOR signaling pathway. *Onco Targets Ther*. 2019;12:5563–5575. <u>https://doi.org/10.2147/</u>OTT.S204715 (RETRACTED).
- The image from Figure 5C, SiHa, si-ST7-AS1+miR-543 inhibitor, has been duplicated with the image from Figure 6C, MGC-803, si-NC, from Wang X, Chen X, Tian Y, Jiang D, Song Y. Long Noncoding RNA RGMB-AS1 Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation. *Onco Targets Ther.* 2020;13:1691–1704. https://doi.org/10.2147/OTT.S234144 (RETRACTED).
- The image from Figure 5D, C-33A, si-ST7-AS1+miR-543 inhibitor, has been duplicated with the image from Figure 4F, U2OS, si-NC, from Zhao X, Li J, Yu D. MicroRNA-939-5p directly targets IGF-1R to inhibit the aggressive phenotypes of osteosarcoma through deactivating the PI3K/Akt pathway. *Int J Mol Med.* 2019;44:1833–1843. https://doi.org/10.3892/ijmm.2019.4333 (RETRACTED).

When approached for an explanation, the authors have been unable to address the concerns raised and have not been able to provide sufficient original data from their study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The authors listed in this publication have been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

581

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S430214

OncoTargets and Therapy 2023:16 581

© 2023 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraph 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).